Ghassan M. Saed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ghassan M. Saed has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Michael P. Diamond
Augusta University, 1120 15th Street, Augusta, GA 30912, USA
31 shared publications Nicole M. Fletcher
Wayne State Univ, Detroit, MI USA
26 shared publicationsHusam M. Abu-Soud
Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI, USA
10 shared publicationsMohammed G. Saed
Department of Obstetrics and Gynecology, C. S. Mott Center for Human Growth and Development, Wayne State University School of Medicine, Detroit, Michigan
7 shared publicationsRobert T. Morris
Department of Gynecologic Oncology, Karmanos Cancer Institute, Detroit, USA
7 shared publicationsZhong L. Jiang
Department of Obstetrics and Gynecology, The C.S. Mott Center for Human Growth and Development, Wayne State University School of Medicine, Detroit, MI, USA
7 shared publications
Latest Publications
- Open Access
- 25 July 2026
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 19 (1)
From cytoreduction to precision oncology: evolution of ovarian cancer therapy
Ovarian cancer remains the most lethal gynecologic malignancy due to its asymptomatic progression, limited screening modalities, and late-stage diagnosis.
- 25 July 2026
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 19 (1)
Open AccessFrom cytoreduction to precision oncology: evolution of ovarian cancer therapy
Ovarian cancer remains the most lethal gynecologic malignancy due to its asymptomatic progression, limited screening modalities, and late-stage diagnosis.
- Open Access
- 22 June 2026
- Published by Elsevier in SSRN Electronic Journal
Sulfotransferase Family 1C Member 2 Serves as a Prognostic Biomarker and Potential Therapeutic Target in Ovarian Cancer
Purpose Ovarian cancer remains the deadliest gynecologic malignancy, with limited prognostic biomarkers and few effective targeted therapies. SULT1C2, a xenobiotic‑metabolizing enzyme implicated in drug response and chemoresistance, has not been characterized in ovarian cancer. This study evaluated its expression, prognostic relevance, molecular associations, and exon 4 variants across ovarian cancer histotypes and stages.Experimental Design Transcriptomic and proteomic datasets from TCGA, GEPIA, CPTAC, and GEO were analyzed to assess differential expression, survival outcomes, gene correlations, histotype‑specific patterns, and exon 4 variants. Functional validation included ELISA, quantitative real‑time PCR, and chemoresistant ovarian cancer cell models. Variant analysis was performed in early‑stage tumors (n = 96).Results SULT1C2 was significantly overexpressed in ovarian tumors compared with normal ovarian tissue (p < 0.05). High expression was associated with improved overall survival (HR = 0.76, p = 0.024). SULT1C2 showed weak but significant correlations with BRCA1, BRCA2, BRAF, HE4, and KRAS, and an inverse correlation with MUC16, with no association with TP53. Mucinous carcinomas demonstrated the highest expression at transcriptomic and proteomic levels (fold change = 1.8, FDR < 0.05). Variant analysis identified nonsynonymous exon 4 mutations in early‑stage tumors, including predicted deleterious substitutions. Chemoresistant ovarian cancer cell lines exhibited increased SULT1C2 expression at mRNA and protein levels.Conclusions SULT1C2 is upregulated in ovarian cancer, enriched in mucinous histology, and associated with favorable survival. Its molecular associations and induction during chemoresistance support its potential as a prognostic biomarker and therapeutic target.
- 22 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSulfotransferase Family 1C Member 2 Serves as a Prognostic Biomarker and Potential Therapeutic Target in Ovarian Cancer
Purpose Ovarian cancer remains the deadliest gynecologic malignancy, with limited prognostic biomarkers and few effective targeted therapies. SULT1C2, a xenobiotic‑metabolizing enzyme implicated in drug response and chemoresistance, has not been characterized in ovarian cancer. This study evaluated its expression, prognostic relevance, molecular associations, and exon 4 variants across ovarian cancer histotypes and stages.Experimental Design Transcriptomic and proteomic datasets from TCGA, GEPIA, CPTAC, and GEO were analyzed to assess differential expression, survival outcomes, gene correlations, histotype‑specific patterns, and exon 4 variants. Functional validation included ELISA, quantitative real‑time PCR, and chemoresistant ovarian cancer cell models. Variant analysis was performed in early‑stage tumors (n = 96).Results SULT1C2 was significantly overexpressed in ovarian tumors compared with normal ovarian tissue (p < 0.05). High expression was associated with improved overall survival (HR = 0.76, p = 0.024). SULT1C2 showed weak but significant correlations with BRCA1, BRCA2, BRAF, HE4, and KRAS, and an inverse correlation with MUC16, with no association with TP53. Mucinous carcinomas demonstrated the highest expression at transcriptomic and proteomic levels (fold change = 1.8, FDR < 0.05). Variant analysis identified nonsynonymous exon 4 mutations in early‑stage tumors, including predicted deleterious substitutions. Chemoresistant ovarian cancer cell lines exhibited increased SULT1C2 expression at mRNA and protein levels.Conclusions SULT1C2 is upregulated in ovarian cancer, enriched in mucinous histology, and associated with favorable survival. Its molecular associations and induction during chemoresistance support its potential as a prognostic biomarker and therapeutic target.
- Open Access
- 13 August 2025
- Published by Elsevier in Translational Oncology
- Vol. 61, 102495
Novel gene rearrangement leads to altered expression of Hornerin in sensitive and chemoresistant ovarian cancer
- 13 August 2025
- Published by Elsevier in Translational Oncology
- Vol. 61, 102495
Open AccessNovel gene rearrangement leads to altered expression of Hornerin in sensitive and chemoresistant ovarian cancer
- 8 April 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (6) , 2029-2037
Anti-Mullerian hormone (AMH) protects ovarian follicle loss by downregulating granulosa cell function in in vitro and in vivo models
Purpose AMH inhibits hormone production in luteinized granulosa cells (GCs) and stalls ovarian follicle development in vitro and in vivo. We sought to confirm AMH’s mechanism of action through SMAD activation and investigate AMH inhibition of follicle development and function, in vitro and in vivo. Methods A primary culture of GCs isolated from follicular fluid was used, and cells were treated with recombinant AMH (rAMH) or placebo for 24 h. For the mouse model, 18-weeks old C57BL female mice were either euthanized at the beginning or treated with rAMH or normal saline for 3 weeks. Primordial (PDF), primary follicle (PRF), secondary (SEF), and tertiary follicles (TEF) were calculated. Real-time RT-PCR and ELISA were performed to quantify GC gene expression and protein translation of human SMAD 1, 5, and 8, FSH-R and mouse FSH-R, inhibin B, caspase 3, Ki67, BMP15, GDF9, and the epigenetic regulators miRNAa and b. Results In vitro, rAMH-treated GC showed activation of the SMAD 1, 5 and downregulation of SMAD 8, with greater magnitude at increasing rAMH doses (p < 0.04) and consequential control of downstream regulators. In vivo, the rAMH-treated mice showed increased SEFs and decreased PRFs while PDFs, TEFs, were unchanged compared with baseline. Compared with Placebo, the rAMH group showed increased PDFs, while PRFs, and TEFs were significantly decreased, and SEFs were unchanged. Conclusions AMH caused SMAD activation in a dose-dependent manner, with downstream downregulation of cell function and replication, also through activation of miRNAs. These mechanisms were confirmed by the in vivo findings with ultimate downregulation of follicular development and preservation of the ovarian follicle number. Counteracting follicular depletion, AMH could be used to protect the ovarian follicle reservoir.
- 8 April 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (6) , 2029-2037
Anti-Mullerian hormone (AMH) protects ovarian follicle loss by downregulating granulosa cell function in in vitro and in vivo models
Purpose AMH inhibits hormone production in luteinized granulosa cells (GCs) and stalls ovarian follicle development in vitro and in vivo. We sought to confirm AMH’s mechanism of action through SMAD activation and investigate AMH inhibition of follicle development and function, in vitro and in vivo. Methods A primary culture of GCs isolated from follicular fluid was used, and cells were treated with recombinant AMH (rAMH) or placebo for 24 h. For the mouse model, 18-weeks old C57BL female mice were either euthanized at the beginning or treated with rAMH or normal saline for 3 weeks. Primordial (PDF), primary follicle (PRF), secondary (SEF), and tertiary follicles (TEF) were calculated. Real-time RT-PCR and ELISA were performed to quantify GC gene expression and protein translation of human SMAD 1, 5, and 8, FSH-R and mouse FSH-R, inhibin B, caspase 3, Ki67, BMP15, GDF9, and the epigenetic regulators miRNAa and b. Results In vitro, rAMH-treated GC showed activation of the SMAD 1, 5 and downregulation of SMAD 8, with greater magnitude at increasing rAMH doses (p < 0.04) and consequential control of downstream regulators. In vivo, the rAMH-treated mice showed increased SEFs and decreased PRFs while PDFs, TEFs, were unchanged compared with baseline. Compared with Placebo, the rAMH group showed increased PDFs, while PRFs, and TEFs were significantly decreased, and SEFs were unchanged. Conclusions AMH caused SMAD activation in a dose-dependent manner, with downstream downregulation of cell function and replication, also through activation of miRNAs. These mechanisms were confirmed by the in vivo findings with ultimate downregulation of follicular development and preservation of the ovarian follicle number. Counteracting follicular depletion, AMH could be used to protect the ovarian follicle reservoir.
- Open Access
- 14 January 2025
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 33 (1) , 200932
Attenuated titin protein expression is associated with advanced stages of ovarian cancer
- 14 January 2025
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 33 (1) , 200932
Open AccessAttenuated titin protein expression is associated with advanced stages of ovarian cancer
- 1 September 2024
- Published by Edizioni Minerva Medica in Minerva Obstetrics and Gynecology
- Vol. 76 (4) , 335-342
The potential benefits of dinitrophenol combination with chemotherapy in the treatment of ovarian cancer
Article: The potential benefits of dinitrophenol combination with chemotherapy in the treatment of ovarian cancer - Minerva Obstetrics and Gynecology 2022 Oct 18 - Minerva Medica - Journals
- 1 September 2024
- Published by Edizioni Minerva Medica in Minerva Obstetrics and Gynecology
- Vol. 76 (4) , 335-342
The potential benefits of dinitrophenol combination with chemotherapy in the treatment of ovarian cancer
Article: The potential benefits of dinitrophenol combination with chemotherapy in the treatment of ovarian cancer - Minerva Obstetrics and Gynecology 2022 Oct 18 - Minerva Medica - Journals
- Open Access
- 26 August 2024
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 32 (3) , 200864
Lemur tail kinase 3 serves as a predictor of patient outcomes and a target for the treatment of ovarian cancer
- 26 August 2024
- Published by Elsevier in Molecular Therapy Oncology
- Vol. 32 (3) , 200864
Open AccessLemur tail kinase 3 serves as a predictor of patient outcomes and a target for the treatment of ovarian cancer
- 1 June 2024
- Published by Edizioni Minerva Medica in Minerva Obstetrics and Gynecology
- Vol. 76 (3) , 231-237
Epigenetics: new insights into postoperative adhesion development
Article: Epigenetics: new insights into postoperative adhesion development - Minerva Obstetrics and Gynecology 2022 Oct 12 - Minerva Medica - Journals
- 1 June 2024
- Published by Edizioni Minerva Medica in Minerva Obstetrics and Gynecology
- Vol. 76 (3) , 231-237
Epigenetics: new insights into postoperative adhesion development
Article: Epigenetics: new insights into postoperative adhesion development - Minerva Obstetrics and Gynecology 2022 Oct 12 - Minerva Medica - Journals
- 8 May 2024
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 24 (7) , 485-491
Is there a link between talcum powder, oxidative stress, and ovarian cancer risk?
Introduction: The link between talcum powder use and cancer, particularly ovarian cancer, has been a topic of scientific research and legal debate for several years. Studies have suggested a potential association between long-term talcum powder use in the genital area and an increased risk of ovarian cancer. Areas Covered: The following report includes up-to-date evidence to support the potential link between talcum powder use and the risk of developing ovarian cancer. The International Agency for Research on Cancer, which is part of the World Health Organization, classified talc-based body powder as possibly carcinogenic to humans when used in the female genital area. However, other studies have not consistently supported this association, and thus more research is needed to establish a clear and definitive link between talcum powder use and cancer. Despite this, recent molecular-level data have linked talc to alterations in redox balance, gene mutations, and inflammatory responses. Specifically, we have identified a role for talc to induce the pro-oxidant state, inhibit apoptosis, and more importantly induced cellular transformation in normal ovarian cells. Expert Opinion: We presented unequivocal evidence to support our opinion that talc is not biologically inert and induces molecular changes that mimic the hallmarks of cancer.
- 8 May 2024
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 24 (7) , 485-491
Is there a link between talcum powder, oxidative stress, and ovarian cancer risk?
Introduction: The link between talcum powder use and cancer, particularly ovarian cancer, has been a topic of scientific research and legal debate for several years. Studies have suggested a potential association between long-term talcum powder use in the genital area and an increased risk of ovarian cancer. Areas Covered: The following report includes up-to-date evidence to support the potential link between talcum powder use and the risk of developing ovarian cancer. The International Agency for Research on Cancer, which is part of the World Health Organization, classified talc-based body powder as possibly carcinogenic to humans when used in the female genital area. However, other studies have not consistently supported this association, and thus more research is needed to establish a clear and definitive link between talcum powder use and cancer. Despite this, recent molecular-level data have linked talc to alterations in redox balance, gene mutations, and inflammatory responses. Specifically, we have identified a role for talc to induce the pro-oxidant state, inhibit apoptosis, and more importantly induced cellular transformation in normal ovarian cells. Expert Opinion: We presented unequivocal evidence to support our opinion that talc is not biologically inert and induces molecular changes that mimic the hallmarks of cancer.
- 1 April 2023
- Published by Edizioni Minerva Medica in Minerva Obstetrics and Gynecology
- Vol. 75 (2) , 150-157
Talcum powder induces malignant transformation in normal human primary ovarian epithelial cells
Article: Talcum powder induces malignant transformation in normal human primary ovarian epithelial cells - Minerva Obstetrics and Gynecology 2021 Nov 26 - Minerva Medica - Journals
- 1 April 2023
- Published by Edizioni Minerva Medica in Minerva Obstetrics and Gynecology
- Vol. 75 (2) , 150-157
Talcum powder induces malignant transformation in normal human primary ovarian epithelial cells
Article: Talcum powder induces malignant transformation in normal human primary ovarian epithelial cells - Minerva Obstetrics and Gynecology 2021 Nov 26 - Minerva Medica - Journals